Articles & Resources

Science
Jul 8, 2024

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Therapy

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Therapy

Read article
Unlocking the Potential of Antibody-Drug Conjugates in Cancer Therapy
Science
Jul 8, 2024

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Therapy

FluoSphera and Revvity Collaborate to Develop a Multiplexed Selectivity Assay for In Vitro Drug Discovery
Science
Jun 11, 2024

FluoSphera and Revvity Collaborate to Develop a Multiplexed Selectivity Assay for In Vitro Drug Discovery

ENMEDIA Talks With FluoSphera
Science
May 26, 2024

ENMEDIA Talks With FluoSphera

FluoSphera S.A. is Grant Award Recipient of CHF 1.1 million from Innosuisse
Science
Jan 1, 2024

FluoSphera S.A. is Grant Award Recipient of CHF 1.1 million from Innosuisse

FluoSphera secures $1 million pre-seed investment
Investment
Mar 1, 2023

FluoSphera secures $1 million pre-seed investment

LSCV Interview
Investment
Jul 26, 2022

LSCV Interview

Things move fast in drug discovery,
so don't get left behind.

‍Subscribe to our Investor Newsletter to keep up with‍ FluoSphera’s milestones ahead of the next fundraising round

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

A Powerful Offering for Drug Discovery

Integrated Discovery Product

Integrated Program of Systemic Drug Discovery

Selectivity
Product

Discovery of the most
selective therapies

Therapeutic 

Index Product

Selection of drugs with the
best therapeutic index

System-Omics Product

Systemic biomarkers and
drug mode of action for the clinic

Translational
Product

Identification of the
most translatable species